Please use this identifier to cite or link to this item: https://hdl.handle.net/10419/232241 
Year of Publication: 
2020
Series/Report no.: 
Research Paper No. 118
Publisher: 
South Centre, Geneva
Abstract: 
The unprecedented global health crisis caused by the coronavirus (COVID-19) pandemic since the first quarter of 2020 has reopened the now-urgent discussion about the role of local pharmaceutical production in addressing the health needs in developing countries. The COVID-19 crisis has highlighted the interdependencies in the global production of pharmaceuticals—no country is self-sufficient. Many industrialized countries are making the decision to repatriate or initiate the production of active pharmaceutical ingredients (APIs) and medicines. Governments are beginning to talk about ‘pharmaceutical sovereignty’ or ‘health security’. If this becomes a reality and the production of pharmaceuticals is led by nationalistic policies, developing countries that still lack manufacturing capacity will have to start or expand the local production of pharmaceuticals, whether at the national or regional level. The war to get access to the future vaccine for COVID-19 does not look easy with these new developments.
Subjects: 
Access to COVID-19 Tools (Accelerator) - (ACT)
Access to Medicines
Biologics
Coronavirus
COVAX Facility
COVID-19
Diagnostics
Global Health
Global Preparedness
Health
Health Security
Innovation
Intellectual Property
Pandemic
Pharmaceutical Sovereignty
Public Health
Research and Development (R&D)
Tech Access Partnership (TAP)
United Nations (UN)
United Nations Conference on Trade and Development (UNCTAD)
United Nations Development Programme (UNDP)
United Nations Industrial Development Organization (UNIDO)
Vaccine Nationalism
Vaccines
WHO
World Health Organization (WHO)
Document Type: 
Research Report
Appears in Collections:

Files in This Item:
File
Size





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.